935854-36-7Relevant articles and documents
THERAPEUTIC AGENTS TARGETING GPR35
-
Paragraph 00151; 00158, (2022/02/05)
Described herein are GPR35 modulators and methods of using these compounds in the treatment of diseases, disorders or conditions. Also described herein are pharmaceutical compositions containing such compounds.
3-(5-Amino-6-oxo-1,6-dihydropyridazin-3-yl)-biphenyl derivatives as PDE4 inhibitors
-
Page/Page column 26-27, (2012/01/03)
New pyridazin-3(2H)-one derivatives having the chemical structure of formula (I) are disclosed; as well as process for their preparation, pharmaceutical compositions comprising them and their use in therapy as inhibitors of the phosphodiesterase IV (PDE4).
(3-oxo)pyridazin-4-ylurea derivatives as PDE4 inhibitors
-
Page/Page column 54, (2010/07/03)
New (3-oxo)pyridazin-4-ylurea derivatives having the chemcial structure of formula (I) are disclosed; as well as process for their preparation, pharmaceutical compositions comprising them and their use in therapy as inhibitors of the phosphodiesterase IV (PDE4).